A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood
Status:
Not yet recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the possible effect of multiple oral doses
of BI 425809 on the steady state pharmacokinetics of ethinylestradiol (EE) and levonogestrel
(LNG) (administered as the combined oral contraceptive Microgynon®).
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
BI 425809 Ethinyl Estradiol-Norgestrel Combination Ethinyl estradiol, levonorgestrel drug combination